This episode of The Motley Fool's Market Checkup is dedicated to the world's largest pure play biotech stock, Gilead Sciences (NASDAQ:GILD)Market Checkup gives a full examination of Gilead's second-quarter results, takes a closer look at the company's current product portfolio, and analyzes the future drugs that have investors excited about the stock's future.

In this video, health care analysts David Williamson and Max Macaluso drill down on Gilead's strong drug development pipeline. Watch and find out why investors should be excited about Gilead's diversification into hepatitis-C treatments and why a drug currently under FDA review is poised to become a megablockbuster.

Follow David on Twitter: @MotleyDavid.